Enfusion, Inc. (NYSE:ENFN) Receives Average Rating of “Reduce” from Analysts

Enfusion, Inc. (NYSE:ENFN) has received an average recommendation of “Reduce” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.33.

Separately, Morgan Stanley started coverage on shares of Enfusion in a research report on Friday, May 10th. They set an “overweight” rating and a $11.00 price objective on the stock.

Insider Transactions at Enfusion

In other Enfusion news, Director Deirdre Somers sold 4,629 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $8.40, for a total transaction of $38,883.60. Following the completion of the sale, the director now directly owns 43,312 shares of the company’s stock, valued at $363,820.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Deirdre Somers sold 4,629 shares of Enfusion stock in a transaction on Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the transaction, the director now directly owns 43,312 shares in the company, valued at $363,820.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bronwen Bastone sold 10,539 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total value of $86,103.63. Following the completion of the sale, the insider now owns 217,154 shares of the company’s stock, valued at approximately $1,774,148.18. The disclosure for this sale can be found here. Insiders have sold 36,318 shares of company stock worth $296,688 in the last quarter. Company insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

Several large investors have recently added to or reduced their stakes in the company. Brown Capital Management LLC raised its position in shares of Enfusion by 6.5% during the 4th quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after purchasing an additional 724,502 shares during the period. Vanguard Group Inc. lifted its position in shares of Enfusion by 17.2% in the third quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock valued at $31,286,000 after acquiring an additional 512,479 shares in the last quarter. Scalar Gauge Management LLC bought a new position in shares of Enfusion in the fourth quarter worth about $1,993,000. Wasatch Advisors LP grew its position in shares of Enfusion by 34.2% during the first quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock worth $7,327,000 after purchasing an additional 201,771 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in Enfusion during the 1st quarter valued at approximately $452,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Stock Performance

Shares of ENFN stock opened at $9.69 on Friday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 323.11, a price-to-earnings-growth ratio of 2.20 and a beta of 0.92. Enfusion has a one year low of $7.52 and a one year high of $10.95. The company’s 50-day moving average is $8.87 and its 200 day moving average is $8.96.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The firm had revenue of $48.05 million for the quarter, compared to analysts’ expectations of $47.67 million. During the same quarter in the previous year, the company earned $0.04 EPS. As a group, research analysts predict that Enfusion will post 0.09 earnings per share for the current fiscal year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.